New Rochelle, NY, March 5, 2009—Serious flaws in a recent study, which concluded that high doses of vitamin C reduce the effectiveness of chemotherapeutic drugs in the treatment of cancer, are revealed in the current issue of Alternative and Complementary Therapies, a journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). This report is available free online at www.liebertpub.com/act
In the Medical Journal Watch column of the latest issue, Jack Challem, a personal nutrition coach and nutrition author from Tucson, Arizona, and a regular contributor to the Journal, challenges the findings of a study published in Cancer Research (2008;68:8031-8038), in which the authors conclude that vitamin C given to mice or cultured cells treated with common anti-cancer drugs reduces the antitumor effects of the chemotherapeutic agents.
Challem points out two main problems with the study: the oxidized form of vitamin C (dehydroascorbic acid) and not actual vitamin C (ascorbic acid) was used; and in the mouse experiments, the animals were given toxic doses of dehydroascorbic acid, a compound that is not used as a dietary supplement in humans.
“This study and the subsequent headlines [it generated] were a grievous disservice to physicians and patients with cancer,” says Challem. He adds that “considerable positive research…has shown striking benefits from high-dose vitamin C (ascorbic acid) in cancer cells and animals-and in actual human beings.”
High-dose intravenous vitamin C is a common form of alternative and complementary therapy for patients receiving chemotherapeutic drugs and is believed to help bring about tumor cell death. In addition, it may promote postsurgical healing by enhancing collagen formation, and increase tissue resistance to tumor spread.
Challem suggests that, “The ideal therapeutic approach would be to tailor individual treatment, including IV vitamin C, from a menu of options.”
Alternative and Complementary Therapies is a bimonthly journal that publishes original research articles, reviews, and commentaries evaluating alternative therapies and how they can be integrated into clinical practice. Topics include botanical medicine, vitamins and supplements, nutrition and diet, mind-body medicine, acupuncture and Traditional Chinese Medicine, ayurveda, indigenous medicine systems, homeopathy, naturopathy, yoga and meditation, manual therapies, energy medicine, and spirituality and health. A complete table of contents and free sample issue may be viewed online at www.liebertpub.com/act
Mary Ann Liebert, Inc. (www.liebertpub.com), is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including The Journal of Alternative & Complementary Medicine, Medical Acupuncture, and Journal of Medicinal Food. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN) , was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 60 journals, books, and newsmagazines is available at www.liebertpub.com